196 related articles for article (PubMed ID: 10882149)
1. Prevention of early postmenopausal bone loss with cyclical etidronate.
Adami S; Bruni V; Bianchini D; Becorpi A; Lombardi P; Campagnoli C; Ferrari A; Marchesoni T; Balena R
J Endocrinol Invest; 2000 May; 23(5):310-6. PubMed ID: 10882149
[TBL] [Abstract][Full Text] [Related]
2. The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study.
Heath DA; Bullivant BG; Boiven C; Balena R
J Clin Densitom; 2000; 3(1):27-33. PubMed ID: 10745299
[TBL] [Abstract][Full Text] [Related]
3. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
Diamond T; McGuigan L; Barbagallo S; Bryant C
Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
[TBL] [Abstract][Full Text] [Related]
4. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
Fogelman I; Herd RJ; Blake GM; Balena R
Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
[TBL] [Abstract][Full Text] [Related]
5. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
Struys A; Snelder AA; Mulder H
Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
[TBL] [Abstract][Full Text] [Related]
6. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
[TBL] [Abstract][Full Text] [Related]
7. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.
Watts NB; Becker P
Bone; 1999 Jan; 24(1):65-8. PubMed ID: 9916786
[TBL] [Abstract][Full Text] [Related]
8. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up).
Meunier PJ; Confavreux E; Tupinon I; Hardouin C; Delmas PD; Balena R
J Clin Endocrinol Metab; 1997 Sep; 82(9):2784-91. PubMed ID: 9284696
[TBL] [Abstract][Full Text] [Related]
9. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
Montessori ML; Scheele WH; Netelenbos JC; Kerkhoff JF; Bakker K
Osteoporos Int; 1997; 7(1):52-8. PubMed ID: 9102064
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
[TBL] [Abstract][Full Text] [Related]
11. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
Geusens P; Dequeker J; Vanhoof J; Stalmans R; Boonen S; Joly J; Nijs J; Raus J
Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
[TBL] [Abstract][Full Text] [Related]
12. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
14. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Mortensen L; Charles P; Bekker PJ; Digennaro J; Johnston CC
J Clin Endocrinol Metab; 1998 Feb; 83(2):396-402. PubMed ID: 9467547
[TBL] [Abstract][Full Text] [Related]
15. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment.
Miller PD; Watts NB; Licata AA; Harris ST; Genant HK; Wasnich RD; Ross PD; Jackson RD; Hoseyni MS; Schoenfeld SL; Valent DJ; Chesnut CH
Am J Med; 1997 Dec; 103(6):468-76. PubMed ID: 9428829
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with etidronate in osteoporosis.
Ryan PJ; Fogelman I
Clin Rheumatol; 1994 Sep; 13(3):455-8. PubMed ID: 7835009
[TBL] [Abstract][Full Text] [Related]
17. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
Masud T; Mulcahy B; Thompson AV; Donnelly S; Keen RW; Doyle DV; Spector TD
Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
[TBL] [Abstract][Full Text] [Related]
18. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation.
Orme SM; Simpson M; Stewart SP; Oldroyd B; Westmacott CF; Smith MA; Belchetz PE
Clin Endocrinol (Oxf); 1994 Aug; 41(2):245-50. PubMed ID: 7923830
[TBL] [Abstract][Full Text] [Related]
19. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
20. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]